One vaccine against new coronavirus is under development by scientists in Israel. They claim to be able to elaborate an active component for immunization soon. The chief of professionals, Dr. Chen Katz, in an interview with The Jerusalem Post, announced that the intention is to start testing on humans in two months, on June 1st.
“We are already in the final stages and in a few days we will have the proteins – the active components of the vaccine”, stressed the leader of the biotechnology group at the Galilee Research Institute (MIGAL).
see more
AMAZING: Scientists find 'prehistoric' penguin alive in New…
‘Atlânticas’ program takes black, indigenous and quilombola women to…
The progress came from the team's dedication, four years ago, to the conception of a vaccine for the virus Infectious Bronchitis of Chickens (BIG), common in birds and pheasants. Therefore, the drug being developed for Covid-19 would be an adaptation of the initial research.
“Our basic concept was to develop a general technology and not a specific vaccine for this or that type of virus”, highlighted Katz. He also explained the genetic adjustments made so that they could adapt the substance for use in humans.
“The scientific structure of the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein, which delivers viral antigen to mucosal tissues by self-activated endocytosis, causing the body to form antibodies against the virus. virus".
The research received funding from the Israeli Ministry of Science and Technology. Also on February 27, Minister Ofir Akunes had already anticipated essential approvals for agility in the process of finalizing and marketing the vaccine.
Additionally, Dr. Katz points out that the drug's oral substance has been proven to induce high levels of antibodies against BIG.
Another conclusion of the multidisciplinary research was that the virus located in chickens has a high genetic approximation with the form of Covid-19 that infects humans, sharing the same method of infection.
“Our goal is to produce the vaccine within the next eight to ten weeks, to reach safety approval in 90 days. This vaccine will be oral, making it particularly accessible to the general public,” said David Zigdon, President of MIGAL.
ATTENTION! We emphasize that there is still no vaccine against the coronavirus. Several scientists, in different countries and continents, began to study and develop drugs for testing.
* With State information
You may also like:
